A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study.

Trial Profile

A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Pasireotide (Primary) ; Everolimus
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms COOPERATE-2
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 06 Mar 2017 Primary endpoint has not been met. (Progression-free survival rate)
    • 06 Mar 2017 Results published in the Annals of Oncology
    • 26 Oct 2016 Status changed from completed to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top